Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Prognostic Value of Multi-Drug Resistance 1 Gene (MDR1) Expression in Newly Diagnosed Patients with Chronic Myeloid Leukemia on Nilotinib Treatment—a Subanalysis of the ENEST1st Study

Christian Dietz, PhD, Michael Lauseker, PhD, Benjamin Hanfstein, MD, Philippe Rousselot, MD, Thoralf Lange, MD, Jacqueline Maier, PhD, Letizia Foroni, Gareth Gerrard, Rodica Talmaci, PhD, Jeroen JWM Janssen, MD, Oliver Frank, PhD, Susanne Saussele, MD, Frank Giles, MDMB, Andreas Hochhaus, MD, Martin C. Müller, MD

Blood (2014) 124 (21): 3144.

https://doi.org/10.1182/blood.V124.21.3144.3144

Published: 2014

Journal Articles

No Improvement Of Overall Survival After Extended Follow-Up Of Donor Versus No Donor Analysis Of Newly Diagnosed Myeloma Patients Included In The HOVON 50/54 Study

Henk Lokhorst, Bronno van der Holt, PhD, Jan Cornelissen, MD, PhD, Marie José Kersten, MD, PhD, Marinus H.J. Van Oers, MD, PhD, Reinier Raymakers, MD, PhD, Monique C. Minnema, MD PhD, Sonja Zweegman, MD PhD, Jeroen JWM Janssen, MD, Mark Zijlmans, MD, Gerard M.J. Bos, Prof MD PhD, Nicolaas PM Schaap, MD, PhD, Okke de Weerdt, Shulamiet Wittebol, MD, Rianne Ammerlaan, Pieter Sonneveld, MD, Ph.D

Blood (2013) 122 (21): 2132.

https://doi.org/10.1182/blood.V122.21.2132.2132

Published: 2013

Journal Articles

Impact of Chronic Graft-Versus-Host disease (GVHD) After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) As Treatment for Acute Myeloid Leukemia (AML): A Survey From the Acute Leukemia Working Party of the EBMT

Frederic Baron, MD, PhD, Myriam Labopin, MD, MS, Dietger Niederwieser, MD, noel-Jean Milpied, MD, Jan J Cornelissen, MD PhD, Claes Malm, MD, Lars Vindelov, MD, Didier Blaise, MD, Jeroen JWM Janssen, MD, Eefke J Petersen, MD PhD, Gerard Socie, Vanderson Rocha, MD, PhD, Arnon Nagler, Mohamad Mohty

Blood (2011) 118 (21): 321.

https://doi.org/10.1182/blood.V118.21.321.321

Published: 2011

Journal Articles

Preliminary Results From a Phase III Trial of Imatinib Versus Imatinib in Combination with Cytarabine in Patients with First Chronic Phase Myeloid Leukemia

Noortje Thielen, Bronno van der Holt, Jan J Cornelissen, MD PhD, Rianne Ammerlaan, Pieter Sonneveld, MD, PhD, Marie José Kersten, J.H. Frederik Falkenburg, Harm Sinnige, Martin Schipperus, Anton Schattenberg, Marinus van Marwijk Kooy, Willem Smit, Gregor Verhoef, Isabel Chu, Peter Valk, Jeroen JWM Janssen, MD PhD, Gert Ossenkoppele, MD, PhD

Blood (2011) 118 (21): 2758.

https://doi.org/10.1182/blood.V118.21.2758.2758

Published: 2011

Journal Articles

Double Umbilical Cord Blood Transplantation Preceded by a Reduced-Intensity Conditioning Regimen: Rapid Induction of Single Donor Chimerism and Highly Predictive Value of Early CD4+ T Cell and NK Cell Predominance

Judith AE Somers, MD, Anneke Brand, MD PhD, Bronno van der Holt, PhD, Yvette van Hensbergen, PhD, Kees Sintnicolaas, MD PhD, Machteld Oudshoorn, PhD, Arend Mulder, PhD, Eric Braakman, PhD, Cynthia Huisman, MD PhD, Jeroen JWM Janssen, MD PhD, Erik WAF Marijt, MD PhD, Eefke J Petersen, MD PhD, Marlies Groenendijk-Sijnke, Jan J Cornelissen, MD PhD

Blood (2011) 118 (21): 3026.

https://doi.org/10.1182/blood.V118.21.3026.3026

Published: 2011

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Improves Outcome As Compared to Conventional Consolidation in Patients Aged 40–60 Years with AML in CR1 with Apparent Greater Benefit for Reduced Intensity Rather Than Myeloablative Conditioning

Blood (2011) 118 (21): 159.

https://doi.org/10.1182/blood.V118.21.159.159

Published: 2011

Journal Articles

Comparison of Low Dose Total Body Irradiation (TBI)-Based Reduced Intensity Conditioning (RIC) Vs. Chemotherapy-Based RIC Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1): a Retrospective Analysis of 1200 Patients From the Acute Leukemia Working Party of EBMT.

Mohamad Mohty, MD, PhD, Myriam Labopin, Jeroen JWM Janssen, MD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, J. J. Cornelissen, Noel-Jean Milpied, MD, Henrik Sengeloev, Didier Blaise, MD, Eefke Petersen, MD, Hakan Goker, John G. Gribben, Arnon Nagler, Vanderson Rocha, MD, PhD

Blood (2009) 114 (22): 1190.

https://doi.org/10.1182/blood.V114.22.1190.1190

Published: 2009

Journal Articles

Polymorphisms in the Multidrug Resistance Gene MDR1 (ABCB1) Predict for Molecular Resistance in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) Receiving High-Dose Imatinib.

Wendy Deenik, MD, Bronno van der Holt, PhD, Jeroen JWM Janssen, MD, Isabel W.T. Chu, Peter Valk, PhD, Gert Ossenkoppele, MD, PhD, Ilse van der Heiden, Pieter Sonneveld, MD, PhD, Ron van Schaik, PhD, Jan J. Cornelissen, MD, PhD

Blood (2009) 114 (22): 2208.

https://doi.org/10.1182/blood.V114.22.2208.2208

Published: 2009

Journal Articles

The Role of In Vivo T-Cell Depletion On Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation From HLA-Identical Siblings in Patients with Follicular Lymphoma: An European Blood and Marrow Transplantation Study.

Julio Delgado, MD, PhD, Carme Canals, MD, Michel Attal, MD, Kirsty Thomson, MD, Antonio Campos, MD, Rodrigo Martino, MD, Timothy James Littlewood, MD, FRCP, Graham H Jackson, MD, Noel-Jean Milpied, MD, Johann Maertens, MD, Ann E. Hunter, MBBS, FRCP, FRCPath, Jeroen JWM Janssen, MD, Silvia Montoto, MD, Anna Sureda, MD, PhD

Blood (2009) 114 (22): 3375.

https://doi.org/10.1182/blood.V114.22.3375.3375

Published: 2009

Journal Articles

Graft-Versus-Leukemia (GVL) Effect After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) as Treatment for Acute Myeloid Leukemia (AML): a Survey From the Acute Leukemia Working Party of the EBMT.

Frederic Baron, Myriam Labopin, Mohamad Mohty, Nadezda Basara, Dietger Niederwieser, Noel-Jean Milpied, J. J. Cornelissen, Claes Malm, Henrik Sengeloev, Didier Blaise, Jeroen JWM Janssen, Eefke Petersen, Gerard Socie, Vanderson Rocha

Blood (2009) 114 (22): 3313.

https://doi.org/10.1182/blood.V114.22.3313.3313

Published: 2009

NARROW

Prognostic Value of Multi-Drug Resistance 1 Gene (MDR1) Expression in Newly Diagnosed Patients with Chronic Myeloid Leukemia on Nilotinib Treatment—a Subanalysis of the ENEST1st Study

No Improvement Of Overall Survival After Extended Follow-Up Of Donor Versus No Donor Analysis Of Newly Diagnosed Myeloma Patients Included In The HOVON 50/54 Study

Impact of Chronic Graft-Versus-Host disease (GVHD) After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) As Treatment for Acute Myeloid Leukemia (AML): A Survey From the Acute Leukemia Working Party of the EBMT

Preliminary Results From a Phase III Trial of Imatinib Versus Imatinib in Combination with Cytarabine in Patients with First Chronic Phase Myeloid Leukemia

Double Umbilical Cord Blood Transplantation Preceded by a Reduced-Intensity Conditioning Regimen: Rapid Induction of Single Donor Chimerism and Highly Predictive Value of Early CD4+ T Cell and NK Cell Predominance

Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Improves Outcome As Compared to Conventional Consolidation in Patients Aged 40–60 Years with AML in CR1 with Apparent Greater Benefit for Reduced Intensity Rather Than Myeloablative Conditioning

Polymorphisms in the Multidrug Resistance Gene MDR1 (ABCB1) Predict for Molecular Resistance in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) Receiving High-Dose Imatinib.

The Role of In Vivo T-Cell Depletion On Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation From HLA-Identical Siblings in Patients with Follicular Lymphoma: An European Blood and Marrow Transplantation Study.

Graft-Versus-Leukemia (GVL) Effect After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) as Treatment for Acute Myeloid Leukemia (AML): a Survey From the Acute Leukemia Working Party of the EBMT.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only